Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Radio-OncologyCOVID-19

Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19

J Thorac Oncol

Warren GW, Lim VS, Chowdhary M, Marwaha G, Abd Elbadee OM, Kirakli EK, Billiet C, Marin AG, Ramos M, Suppli MH, McGinnis GJ, Adjei AA

doi: 10.1016/j.jtho.2021.06.005

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors

Cancer Treat Rev.

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E

doi: 10.1016/j.ctrv.2017.06.001.

Gastrointestinal Cancer

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook Times Oncology Hematology

Palmarocchi MC, Merlo E, Cefali M, De Dosso S

doi: 10.36000/hbT.OH.2021.07.029

Lung, Respiratory and Thoracic Cancer

First-line treatment of ALK-positive NSCLC

healthbook TIMES Oncology Hematology

Bouchaab H

doi: 10.36000/hbT.OH.2019.02.008

Gynecologic Cancer

Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer

Eur J Cancer.

Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, Leunen K, Berteloot P, Moerman P, Vergote I, Vandecaveye V

doi: 10.1016/j.ejca.2017.06.010.

RECOMMENDED

Skin Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

J Immunother.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R

doi: 10.1097/CJI.

SPECIAL REPORT

Genitourinary CancerLung, Respiratory and Thoracic CancerSkin Cancer

Meet the Expert

doi: 10.1056/NEJMoa1504627 (2015).

Breast Cancer

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Oncologist.

Spring LM, Zangardi ML, Moy B, Bardia A

doi: 10.1634/

Related content